Legal Is Not the Same as Safe: What Physicians Should Know Before Prescribing Peptides

Peptides have gone from the endocrinology clinic to the center of the wellness conversation, and physicians are being pulled in two unhelpful directions. One camp dismisses the entire category as snake oil. The other treats anything that looks like a hormone as safe, natural, and worth trying. Neither position holds up when you ask the questions clinicians are trained to ask: what is the molecule, what is the dose, what is the evidence in humans, and who is this patient?

Dr. Elena Christofides has spent her career on the evidence side of that question. She is the founder of Endocrinology Associates in Columbus, Ohio, is board certified in both endocrinology and internal medicine, and is a Fellow of the American College of Endocrinology. She has helped guide or run dozens of clinical studies through her research practice, chaired the AACE Nutrition and Obesity Resource Center, and serves as editor-at-large at MedCentral, where she also co-hosts the podcast Case Breaks.

What is a peptide, and why is the category so confusing?

"It's a class that just describes a series of molecules, long chains of amino acids. That's all they are. They're not drugs by themselves."

Elena starts by stripping away the mystique. A peptide is a chemical description, not a treatment category, and lumping every peptide together obscures more than it reveals. Some of endocrinology's most established drugs are peptides, including insulin, GLP-1 receptor agonists, and parathyroid hormone. She argues that social media and the FDA have both bucketed very different molecules into one group, which she calls scientifically imprecise. Her framework for evaluating any of them starts with the formulation, the dose, the intended use, the target, and the body of human evidence.

Are peptides pseudoscience, or are they all safe?

"After all, insulin is a peptide. Well, if you get too much of it, you could get hypoglycemic and cause significant harm. You get too little of it, you get hyperglycemic and you can die. Both states are not safe."

Elena sees a myth on each side. Clinicians assume that because so many peptides are understudied, the whole field must be pseudoscience. Consumers assume that because peptides resemble hormones or compounds found in nature, they must be safe and effective. She calls both views overly simplistic, and uses the most familiar peptide in medicine to show why: too much insulin and too little insulin can both cause serious harm.

Are peptides good or bad?

Neither, says Elena, and asking the question that way is the problem. What matters is the dose, the receptor activity, the duration of action, and the consequences of acting on a given target. The endocrine system depends on balance, and the same molecule can help or harm depending on where a patient lands relative to that balance.

Why does manufacturing quality matter as much as the molecule?

"If I buy a vial of a peptide or I buy a vial of insulin, I want to know that I'm getting exactly what I've bought."

For Elena, this is where the popular peptides fall furthest short. A physician prescribing insulin can trust that the vial contains what the label says because the manufacturing process is standardized, certified, and independently verified. She notes that this verification is missing for most of the peptides that are popular on social media, and that it matters for safety as much as for efficacy.

What separates BPC-157 from CJC-1295?

Elena uses two popular examples to show how differently she weighs them. For BPC-157, she says there is plausible human and preclinical data suggesting possible benefit. CJC-1295 bothers her more. It stimulates growth hormone, which she prescribes without hesitation to patients who are deficient, but as a lab-manufactured, third-party tested, FDA-certified product from a regulated pharmacy. Too much growth hormone, she notes, can cause cancer, growth of the hands, feet, and jaw, and heart failure, which is why the range needs to be monitored and levels tested. Her rule of thumb: if a peptide has a counterpart in the normal endocrine world, consider giving that counterpart, and if it does not, make sure the patient understands it must be monitored for safety and efficacy.

What three questions should you ask before using a peptide?

Elena reduces the decision to three questions that every clinician should be able to answer before considering a peptide.

• Is it legal?
• Is it scientifically defensible?
• Is it appropriate for this particular patient?

Where do compounding, off-label use, and "research use only" create legal risk?

"Just because the FDA has stated that it is legal to compound something does not mean that they've voted on the efficacy or safety of that product."

Elena separates three categories that are often blurred together. Compounding: the FDA maintains a list of therapies that may be compounded, with rules around how that is done, but appearing on the list says nothing about efficacy or safety. Off-label use: this means using a legally approved drug for an unintended purpose, which is different from compounding something that is not legal and calling it off-label. Research use only: she warns against waving away the label because a patient agrees, noting that the terms carry legal weight for both the clinician and the patient, and that state rules may matter.

How should physicians document peptide prescribing?

Elena's advice is to be prepared for what goes wrong. That means being clear about what is medically defensible, documenting the conversation with the patient, and recording the expected benefits, expected risks, and timeline of efficacy. She emphasizes that patient consent should be taken verbally and affirmatively. If a patient says they will use a peptide regardless and simply wants safety monitoring, she says she documents that statement word for word in the chart.

How do you talk with a patient who asks about peptides?

"They should not immediately dismiss the patient. You should instead invite the question, 'What problem are you trying to solve?'"

Not with a dismissal. Elena says the first move is to invite the question behind the request, which opens up what has already been tried and which approved therapies might reach the same goal more safely. If nothing approved fits, the conversation shifts to what is known and unknown about the unapproved options.

Where is peptide medicine headed?

Elena is optimistic, and she points to the incretin class as the model. When rigorous clinical trials are applied to peptide molecules, the results can be transformative, and she expects the broader field to keep moving in that direction. She does not know which peptides will prove out over the next five to ten years, but she does not expect the conversation to go away, and she says it should not.

Physicians who want to hear more from Elena can find her clinical research, writing, and podcast work through the links below.

Elena Christofides, MD, FACE, is an endocrinologist, clinical researcher, and founder of Endocrinology Associates in Columbus, Ohio. Learn more at endocrinology-associates.com.

Resources

• Practice: Endocrinology Associates
• Research: Endocrinology Research Associates
• Podcast: Case Breaks, co-hosted with Joseph Winchell, MD
• LinkedIn: linkedin.com/in/elenachristofides